Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660862 · ClinicalTrials.gov registry record · Phase 4
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
A Phase 4 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT06660862 is a Phase 4 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 80 participants.
The verdict
NCT06660862, a Phase 4 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
This prospective clinical trial aims to investigate the impact of darolutamide in combination with standard-of-care androgen deprivation on physical activity, specifically step count, and its correlation with important markers of safety in vulnerable adults who screen positive by a brief geriatric assessment (GA) and metastatic hormone-sensitive prostate cancer.
Interventions
- DRUG Darolutamide
- DRUG Physician choice Androgen Deprivation (Hormone) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-11 |
| Est. Completion | 2029-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660862
The ClinicalTrials.gov registry entry for NCT06660862 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Darolutamide is the first listed.
NCT06660862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06660862 about?
NCT06660862 is a clinical study titled "Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.". This prospective clinical trial aims to investigate the impact of darolutamide in combination with standard-of-care androgen deprivation on physical activity, specifically step count, and its correlation with important markers of safety in vulnerable adults who screen positive by a brief geriatric a...
What is the current status of trial NCT06660862?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-11. Estimated completion is 2029-11.
What interventions are being tested in trial NCT06660862?
The interventions under investigation include: Darolutamide (DRUG), Physician choice Androgen Deprivation (Hormone) Therapy (DRUG).
Who is sponsoring clinical trial NCT06660862?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.